NCT02433340View on ClinicalTrials.gov

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ABT-122

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY